Ergoteles’s AC Immune ACIU Stock Holding History

Ergoteles’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,014	Closed	-$46.8K	–	1001
2023 Q1	$46.8K	Sell	20,014 -52,618	-72%	-$122K	﹤0.01%	1138
2022 Q4	$148K	Buy	+72,632	New	+$187K	0.01%	1153

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Ergoteles's ACIU Position: Q2 2023 in Review

Ergoteles sold out of AC Immune (ACIU) in Q2 2023, closing a stake of 20,014 shares — an estimated $46.8K sold.

Ergoteles first reported a position in ACIU in Q4 2022 and held it in 2 quarters. The position peaked at $148K in Q4 2022. 31 funds tracked by Wall St. Rank hold ACIU as of Q2 2023.

Ergoteles reported no remaining AC Immune position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 20,014 AC Immune shares in Q2 2023, an estimated $46.8K.
Ergoteles first reported a position in AC Immune in Q4 2022 and held it in 2 quarters.
Ergoteles's AC Immune position peaked at $148K in Q4 2022.
31 funds tracked by Wall St. Rank held AC Immune as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.